Xiaoshi Zhu
Research Subjects
Xiaoshi Zhu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Lizhen Zhu
Emergency Care Unit, Sichuan Academy of Medical Sciences and Sichuan People’s Hospital
2 shared publicationsJunchao Deng
Department of Pediatrics, Sichuan Academy of Medical Sciences and Sichuan People’s Hospital
1 shared publication- Junchao Deng
Department of Pediatrics, Sichuan Academy of Medical Sciences and Sichuan People’s Hospital, Qingyang District, Chengdu, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 11 December 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2556486
Immune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome
Steroid-resistant nephrotic syndrome (SRNS) is a complex and refractory kidney disease generally causing chronic kidney dysfunction, characterized by persistent proteinuria despite prolonged corticosteroid therapy. This review comprehensively explores the mechanisms of immunity driving SRNS, mainly focusing on the complex function network within immune cells, pro-inflammatory cytokines, and podocyte injury. Current immunosuppressive therapies show limited efficacy, prompting exploration of precision immunomodulatory strategies. Emerging approaches include IL-17 or low-dose IL-12 modulation, proteasome or CD38 blockade, C5/factor B inhibition, and Rho kinase or caspase inhibition. Additionally, personalized strategies leveraging genetic profiling and biomarker-guided therapies are advancing tailored interventions. These targeted therapies address SRNS heterogeneity while minimizing systemic immunosuppression, offering new promise for halting disease progression. Future directions emphasize combinatorial regimens and mechanistic stratification to optimize therapeutic outcomes.
- 11 December 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2556486
Open AccessImmune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome
Steroid-resistant nephrotic syndrome (SRNS) is a complex and refractory kidney disease generally causing chronic kidney dysfunction, characterized by persistent proteinuria despite prolonged corticosteroid therapy. This review comprehensively explores the mechanisms of immunity driving SRNS, mainly focusing on the complex function network within immune cells, pro-inflammatory cytokines, and podocyte injury. Current immunosuppressive therapies show limited efficacy, prompting exploration of precision immunomodulatory strategies. Emerging approaches include IL-17 or low-dose IL-12 modulation, proteasome or CD38 blockade, C5/factor B inhibition, and Rho kinase or caspase inhibition. Additionally, personalized strategies leveraging genetic profiling and biomarker-guided therapies are advancing tailored interventions. These targeted therapies address SRNS heterogeneity while minimizing systemic immunosuppression, offering new promise for halting disease progression. Future directions emphasize combinatorial regimens and mechanistic stratification to optimize therapeutic outcomes.
- Open Access
- 8 November 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (6) , 1611-1622
Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles
Background: Rituximab is considered a therapeutic option in children with refractory nephrotic syndrome (RNS). However, the efficacy and safety of rituximab treatment remain unclear. Objective: This study systematically evaluated the clinical effectiveness and related adverse event profiles of rituximab compared with other immunosuppressants in children with RNS. Method: Two independent investigators conducted the methodological rigor evaluation in a double-blind manner. Statistical analyses were performed using RevMan 5.4. Results: Relative to other conventional second-line agents, rituximab therapy presented a significantly increased relapse-free survival rate [vs. tacrolimus: OR = 3.42, 95% CI = 1.96–5.94, P < 0.01]. Fewer adverse drug reactions occurred in patients with rituximab than with other immunosuppressants [vs. cyclophosphamide: OR = 0.18, 95% CI = 0.04–0.89, P = 0.03; vs. tacrolimus: OR = 0.26, 95% CI = 0.07–0.92, P = 0.04]. The application of rituximab increased the steroid-discontinued rate and decreased the corticosteroid dose in the treatment [vs. cyclophosphamide: OR = 5.46, 95% CI = 2.00–14.92, P = 0.0009; vs. tacrolimus: OR = 3.42, 95% CI = 1.67–7.01, P = 0.0008]. Conclusion: Our study demonstrates rituximab’s superior efficacy and safety profile compared to conventional second-line immunosuppressants in pediatric RNS, particularly regarding steroid minimization. Systematic review registration number: CRD420251082051. Graphical
- 8 November 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (6) , 1611-1622
Open AccessRituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles
Background: Rituximab is considered a therapeutic option in children with refractory nephrotic syndrome (RNS). However, the efficacy and safety of rituximab treatment remain unclear. Objective: This study systematically evaluated the clinical effectiveness and related adverse event profiles of rituximab compared with other immunosuppressants in children with RNS. Method: Two independent investigators conducted the methodological rigor evaluation in a double-blind manner. Statistical analyses were performed using RevMan 5.4. Results: Relative to other conventional second-line agents, rituximab therapy presented a significantly increased relapse-free survival rate [vs. tacrolimus: OR = 3.42, 95% CI = 1.96–5.94, P < 0.01]. Fewer adverse drug reactions occurred in patients with rituximab than with other immunosuppressants [vs. cyclophosphamide: OR = 0.18, 95% CI = 0.04–0.89, P = 0.03; vs. tacrolimus: OR = 0.26, 95% CI = 0.07–0.92, P = 0.04]. The application of rituximab increased the steroid-discontinued rate and decreased the corticosteroid dose in the treatment [vs. cyclophosphamide: OR = 5.46, 95% CI = 2.00–14.92, P = 0.0009; vs. tacrolimus: OR = 3.42, 95% CI = 1.67–7.01, P = 0.0008]. Conclusion: Our study demonstrates rituximab’s superior efficacy and safety profile compared to conventional second-line immunosuppressants in pediatric RNS, particularly regarding steroid minimization. Systematic review registration number: CRD420251082051. Graphical